The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer
Identifieur interne : 002D98 ( Ncbi/Checkpoint ); précédent : 002D97; suivant : 002D99The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer
Auteurs : Jean Francois Fonteneau [France] ; Fabienne Brilot [Australie] ; Christian Münz [Suisse] ; Monique Gannagé [Suisse]Source :
- The Journal of Immunology Author Choice [ 0022-1767 ] ; 2015.
Descripteurs français
- KwdFr :
- Activation des lymphocytes (immunologie), Acétylcystéine (analogues et dérivés), Acétylcystéine (pharmacologie), Antigènes d'histocompatibilité de classe II (immunologie), Antigènes néoplasiques (immunologie), Autophagie (immunologie), Cellules dendritiques (immunologie), Chloroquine (pharmacologie), Déterminants antigéniques des lymphocytes T (immunologie), Endocytose (immunologie), Humains, Immunothérapie adoptive, Interférence par ARN, Leupeptines, Lignée cellulaire tumorale, Lymphocytes T CD4+ (immunologie), Lymphocytes T CD4+ (transplantation), Mélanome (), Mélanome (immunologie), Petit ARN interférent, Petites protéines modificatrices apparentées à l'ubiquitine (génétique), Protéine de membrane-2 associée au lysosome (génétique), Protéine-12 associée à l'autophagie, Protéines membranaires (immunologie), Présentation d'antigène (immunologie).
- MESH :
- analogues et dérivés : Acétylcystéine.
- génétique : Petites protéines modificatrices apparentées à l'ubiquitine, Protéine de membrane-2 associée au lysosome.
- immunologie : Activation des lymphocytes, Antigènes d'histocompatibilité de classe II, Antigènes néoplasiques, Autophagie, Cellules dendritiques, Déterminants antigéniques des lymphocytes T, Endocytose, Lymphocytes T CD4+, Mélanome, Protéines membranaires, Présentation d'antigène.
- pharmacologie : Acétylcystéine, Chloroquine.
- Humains, Immunothérapie adoptive, Interférence par ARN, Leupeptines, Lignée cellulaire tumorale, Lymphocytes T CD4+, Mélanome, Petit ARN interférent, Protéine-12 associée à l'autophagie.
English descriptors
- KwdEn :
- Acetylcysteine (analogs & derivatives), Acetylcysteine (pharmacology), Antigen Presentation (immunology), Antigens, Neoplasm (immunology), Autophagy (immunology), Autophagy-Related Protein 12, CD4-Positive T-Lymphocytes (immunology), CD4-Positive T-Lymphocytes (transplantation), Cell Line, Tumor, Chloroquine (pharmacology), Dendritic Cells (immunology), Endocytosis (immunology), Epitopes, T-Lymphocyte (immunology), Histocompatibility Antigens Class II (immunology), Humans, Immunotherapy, Adoptive, Leupeptins, Lymphocyte Activation (immunology), Lysosomal-Associated Membrane Protein 2 (genetics), Melanoma (immunology), Melanoma (therapy), Membrane Proteins (immunology), RNA Interference, RNA, Small Interfering, Small Ubiquitin-Related Modifier Proteins (genetics).
- MESH :
- chemical , analogs & derivatives : Acetylcysteine.
- chemical , genetics : Lysosomal-Associated Membrane Protein 2, Small Ubiquitin-Related Modifier Proteins.
- chemical , immunology : Antigens, Neoplasm, Epitopes, T-Lymphocyte, Histocompatibility Antigens Class II, Membrane Proteins.
- chemical , pharmacology : Acetylcysteine, Chloroquine.
- immunology : Antigen Presentation, Autophagy, CD4-Positive T-Lymphocytes, Dendritic Cells, Endocytosis, Lymphocyte Activation, Melanoma.
- therapy : Melanoma.
- transplantation : CD4-Positive T-Lymphocytes.
- chemical : Autophagy-Related Protein 12, Cell Line, Tumor, Humans, Immunotherapy, Adoptive, Leupeptins, RNA Interference, RNA, Small Interfering.
Abstract
NY-ESO-1–specific CD4+ T cells are of interest for immune therapy against tumors, because it has been shown that their transfer into a patient with melanoma resulted in tumor regression. Therefore, we investigated how NY-ESO-1 is processed onto MHC class II molecules for direct CD4+ T cell recognition of melanoma cells. We could rule out proteasome and autophagy-dependent endogenous Ag processing for MHC class II presentation. In contrast, intercellular Ag transfer, followed by classical MHC class II Ag processing via endocytosis, sensitized neighboring melanoma cells for CD4+ T cell recognition. However, macroautophagy targeting of NY-ESO-1 enhanced MHC class II presentation. Therefore, both elevated NY-ESO-1 release and macroautophagy targeting could improve melanoma cell recognition by CD4+ T cells and should be explored during immunotherapy of melanoma.
Url:
DOI: 10.4049/jimmunol.1402664
PubMed: 26608910
PubMed Central: 4683358
Affiliations:
- Australie, France, Suisse
- Canton de Genève, Canton de Zurich, Pays de la Loire
- Genève, Nantes, Zurich
- Université de Genève, Université de Nantes, Université de Zurich
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000203
- to stream Pmc, to step Curation: 000203
- to stream Pmc, to step Checkpoint: 000C79
- to stream PubMed, to step Corpus: 002521
- to stream PubMed, to step Curation: 002453
- to stream PubMed, to step Checkpoint: 002453
- to stream Ncbi, to step Merge: 002D98
- to stream Ncbi, to step Curation: 002D98
Links to Exploration step
PMC:4683358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4<sup>+</sup> T Cells after Intercellular Antigen Transfer</title><author><name sortKey="Fonteneau, Jean Francois" sort="Fonteneau, Jean Francois" uniqKey="Fonteneau J" first="Jean Francois" last="Fonteneau">Jean Francois Fonteneau</name><affiliation wicri:level="4"><nlm:aff id="aff1">INSERM UMR892, CNRS UMR6299, Université de Nantes, Nantes 44007, France;</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR892, CNRS UMR6299, Université de Nantes, Nantes 44007</wicri:regionArea><wicri:noRegion>44007</wicri:noRegion><orgName type="university">Université de Nantes</orgName><placeName><settlement type="city">Nantes</settlement><region type="region" nuts="2">Pays de la Loire</region></placeName></affiliation></author><author><name sortKey="Brilot, Fabienne" sort="Brilot, Fabienne" uniqKey="Brilot F" first="Fabienne" last="Brilot">Fabienne Brilot</name><affiliation wicri:level="1"><nlm:aff id="aff2">Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Kids Research Institute at the Children's Hospital at Westmead, St. Westmead, New South Wales 2145, Australia;</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Kids Research Institute at the Children's Hospital at Westmead, St. Westmead, New South Wales 2145</wicri:regionArea><wicri:noRegion>New South Wales 2145</wicri:noRegion></affiliation></author><author><name sortKey="Munz, Christian" sort="Munz, Christian" uniqKey="Munz C" first="Christian" last="Münz">Christian Münz</name><affiliation wicri:level="4"><nlm:aff id="aff3">Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006, Switzerland;</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006</wicri:regionArea><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region><settlement type="city">Zurich</settlement></placeName><orgName type="university">Université de Zurich</orgName></affiliation></author><author><name sortKey="Gannage, Monique" sort="Gannage, Monique" uniqKey="Gannage M" first="Monique" last="Gannagé">Monique Gannagé</name><affiliation wicri:level="4"><nlm:aff id="aff3">Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006, Switzerland;</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006</wicri:regionArea><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region><settlement type="city">Zurich</settlement></placeName><orgName type="university">Université de Zurich</orgName></affiliation><affiliation wicri:level="4"><nlm:aff wicri:cut="; and" id="aff4">Department of Pathology and Immunology, School of Medicine, University of Geneva, Geneva 1211, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Pathology and Immunology, School of Medicine, University of Geneva, Geneva 1211</wicri:regionArea><orgName type="university">Université de Genève</orgName><placeName><settlement type="city">Genève</settlement><region nuts="3" type="region">Canton de Genève</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="aff5">Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva 1205, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva 1205</wicri:regionArea><wicri:noRegion>Geneva 1205</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26608910</idno><idno type="pmc">4683358</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683358</idno><idno type="RBID">PMC:4683358</idno><idno type="doi">10.4049/jimmunol.1402664</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000203</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000203</idno><idno type="wicri:Area/Pmc/Curation">000203</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000203</idno><idno type="wicri:Area/Pmc/Checkpoint">000C79</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000C79</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">002521</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002521</idno><idno type="wicri:Area/PubMed/Curation">002453</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002453</idno><idno type="wicri:Area/PubMed/Checkpoint">002453</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002453</idno><idno type="wicri:Area/Ncbi/Merge">002D98</idno><idno type="wicri:Area/Ncbi/Curation">002D98</idno><idno type="wicri:Area/Ncbi/Checkpoint">002D98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4<sup>+</sup> T Cells after Intercellular Antigen Transfer</title><author><name sortKey="Fonteneau, Jean Francois" sort="Fonteneau, Jean Francois" uniqKey="Fonteneau J" first="Jean Francois" last="Fonteneau">Jean Francois Fonteneau</name><affiliation wicri:level="4"><nlm:aff id="aff1">INSERM UMR892, CNRS UMR6299, Université de Nantes, Nantes 44007, France;</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>INSERM UMR892, CNRS UMR6299, Université de Nantes, Nantes 44007</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName><orgName type="university">Université de Nantes</orgName></affiliation></author><author><name sortKey="Brilot, Fabienne" sort="Brilot, Fabienne" uniqKey="Brilot F" first="Fabienne" last="Brilot">Fabienne Brilot</name><affiliation wicri:level="1"><nlm:aff id="aff2">Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Kids Research Institute at the Children's Hospital at Westmead, St. Westmead, New South Wales 2145, Australia;</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Kids Research Institute at the Children's Hospital at Westmead, St. Westmead, New South Wales 2145</wicri:regionArea><wicri:noRegion>New South Wales 2145</wicri:noRegion></affiliation></author><author><name sortKey="Munz, Christian" sort="Munz, Christian" uniqKey="Munz C" first="Christian" last="Münz">Christian Münz</name><affiliation wicri:level="4"><nlm:aff id="aff3">Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006, Switzerland;</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006</wicri:regionArea><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region><settlement type="city">Zurich</settlement></placeName><orgName type="university">Université de Zurich</orgName></affiliation></author><author><name sortKey="Gannage, Monique" sort="Gannage, Monique" uniqKey="Gannage M" first="Monique" last="Gannagé">Monique Gannagé</name><affiliation wicri:level="4"><nlm:aff id="aff3">Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006, Switzerland;</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich 8006</wicri:regionArea><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region><settlement type="city">Zurich</settlement></placeName><orgName type="university">Université de Zurich</orgName></affiliation><affiliation wicri:level="4"><nlm:aff wicri:cut="; and" id="aff4">Department of Pathology and Immunology, School of Medicine, University of Geneva, Geneva 1211, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Pathology and Immunology, School of Medicine, University of Geneva, Geneva 1211</wicri:regionArea><orgName type="university">Université de Genève</orgName><placeName><settlement type="city">Genève</settlement><region nuts="3" type="region">Canton de Genève</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="aff5">Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva 1205, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva 1205</wicri:regionArea><wicri:noRegion>Geneva 1205</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Journal of Immunology Author Choice</title><idno type="ISSN">0022-1767</idno><idno type="eISSN">1550-6606</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylcysteine (analogs & derivatives)</term><term>Acetylcysteine (pharmacology)</term><term>Antigen Presentation (immunology)</term><term>Antigens, Neoplasm (immunology)</term><term>Autophagy (immunology)</term><term>Autophagy-Related Protein 12</term><term>CD4-Positive T-Lymphocytes (immunology)</term><term>CD4-Positive T-Lymphocytes (transplantation)</term><term>Cell Line, Tumor</term><term>Chloroquine (pharmacology)</term><term>Dendritic Cells (immunology)</term><term>Endocytosis (immunology)</term><term>Epitopes, T-Lymphocyte (immunology)</term><term>Histocompatibility Antigens Class II (immunology)</term><term>Humans</term><term>Immunotherapy, Adoptive</term><term>Leupeptins</term><term>Lymphocyte Activation (immunology)</term><term>Lysosomal-Associated Membrane Protein 2 (genetics)</term><term>Melanoma (immunology)</term><term>Melanoma (therapy)</term><term>Membrane Proteins (immunology)</term><term>RNA Interference</term><term>RNA, Small Interfering</term><term>Small Ubiquitin-Related Modifier Proteins (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation des lymphocytes (immunologie)</term><term>Acétylcystéine (analogues et dérivés)</term><term>Acétylcystéine (pharmacologie)</term><term>Antigènes d'histocompatibilité de classe II (immunologie)</term><term>Antigènes néoplasiques (immunologie)</term><term>Autophagie (immunologie)</term><term>Cellules dendritiques (immunologie)</term><term>Chloroquine (pharmacologie)</term><term>Déterminants antigéniques des lymphocytes T (immunologie)</term><term>Endocytose (immunologie)</term><term>Humains</term><term>Immunothérapie adoptive</term><term>Interférence par ARN</term><term>Leupeptines</term><term>Lignée cellulaire tumorale</term><term>Lymphocytes T CD4+ (immunologie)</term><term>Lymphocytes T CD4+ (transplantation)</term><term>Mélanome ()</term><term>Mélanome (immunologie)</term><term>Petit ARN interférent</term><term>Petites protéines modificatrices apparentées à l'ubiquitine (génétique)</term><term>Protéine de membrane-2 associée au lysosome (génétique)</term><term>Protéine-12 associée à l'autophagie</term><term>Protéines membranaires (immunologie)</term><term>Présentation d'antigène (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Acetylcysteine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Lysosomal-Associated Membrane Protein 2</term><term>Small Ubiquitin-Related Modifier Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Neoplasm</term><term>Epitopes, T-Lymphocyte</term><term>Histocompatibility Antigens Class II</term><term>Membrane Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Acetylcysteine</term><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acétylcystéine</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Petites protéines modificatrices apparentées à l'ubiquitine</term><term>Protéine de membrane-2 associée au lysosome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Activation des lymphocytes</term><term>Antigènes d'histocompatibilité de classe II</term><term>Antigènes néoplasiques</term><term>Autophagie</term><term>Cellules dendritiques</term><term>Déterminants antigéniques des lymphocytes T</term><term>Endocytose</term><term>Lymphocytes T CD4+</term><term>Mélanome</term><term>Protéines membranaires</term><term>Présentation d'antigène</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antigen Presentation</term><term>Autophagy</term><term>CD4-Positive T-Lymphocytes</term><term>Dendritic Cells</term><term>Endocytosis</term><term>Lymphocyte Activation</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acétylcystéine</term><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Autophagy-Related Protein 12</term><term>Cell Line, Tumor</term><term>Humans</term><term>Immunotherapy, Adoptive</term><term>Leupeptins</term><term>RNA Interference</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Immunothérapie adoptive</term><term>Interférence par ARN</term><term>Leupeptines</term><term>Lignée cellulaire tumorale</term><term>Lymphocytes T CD4+</term><term>Mélanome</term><term>Petit ARN interférent</term><term>Protéine-12 associée à l'autophagie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>NY-ESO-1–specific CD4<sup>+</sup> T cells are of interest for immune therapy against tumors, because it has been shown that their transfer into a patient with melanoma resulted in tumor regression. Therefore, we investigated how NY-ESO-1 is processed onto MHC class II molecules for direct CD4<sup>+</sup> T cell recognition of melanoma cells. We could rule out proteasome and autophagy-dependent endogenous Ag processing for MHC class II presentation. In contrast, intercellular Ag transfer, followed by classical MHC class II Ag processing via endocytosis, sensitized neighboring melanoma cells for CD4<sup>+</sup> T cell recognition. However, macroautophagy targeting of NY-ESO-1 enhanced MHC class II presentation. Therefore, both elevated NY-ESO-1 release and macroautophagy targeting could improve melanoma cell recognition by CD4<sup>+</sup> T cells and should be explored during immunotherapy of melanoma.</p></div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Suisse</li></country><region><li>Canton de Genève</li><li>Canton de Zurich</li><li>Pays de la Loire</li></region><settlement><li>Genève</li><li>Nantes</li><li>Zurich</li></settlement><orgName><li>Université de Genève</li><li>Université de Nantes</li><li>Université de Zurich</li></orgName></list><tree><country name="France"><region name="Pays de la Loire"><name sortKey="Fonteneau, Jean Francois" sort="Fonteneau, Jean Francois" uniqKey="Fonteneau J" first="Jean Francois" last="Fonteneau">Jean Francois Fonteneau</name></region></country><country name="Australie"><noRegion><name sortKey="Brilot, Fabienne" sort="Brilot, Fabienne" uniqKey="Brilot F" first="Fabienne" last="Brilot">Fabienne Brilot</name></noRegion></country><country name="Suisse"><region name="Canton de Zurich"><name sortKey="Munz, Christian" sort="Munz, Christian" uniqKey="Munz C" first="Christian" last="Münz">Christian Münz</name></region><name sortKey="Gannage, Monique" sort="Gannage, Monique" uniqKey="Gannage M" first="Monique" last="Gannagé">Monique Gannagé</name><name sortKey="Gannage, Monique" sort="Gannage, Monique" uniqKey="Gannage M" first="Monique" last="Gannagé">Monique Gannagé</name><name sortKey="Gannage, Monique" sort="Gannage, Monique" uniqKey="Gannage M" first="Monique" last="Gannagé">Monique Gannagé</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002D98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= PMC:4683358
|texte= The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:26608910" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |